Skip to Content

Significant improvements in OS and RFS for older patients with AML

About 40-50% of older patients with AML attain complete remission (CR) with induction chemotherapy but the majority of them eventually relapse. At EHA 2021 Congress, Farhad Ravandi present new data from the QUAZAR AML-001-study. It shows significant improvements in OS and RFS with CC-486, an oral hypomethylating agent. Farhad Ravandi are professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas – M. D. Anderson Cancer Center, Texas, USA.

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top